8-K: BriaPro Therapeutics Corp. Files Interim Financials and Management Discussion

BriaPro Therapeutics Corp., a subsidiary of BriaCell, has released its unaudited interim financial statements and management discussion for the three and nine months ended April 30, 2024.

Summary

• BriaPro Therapeutics Corp., a two-thirds owned subsidiary of BriaCell Therapeutics Corp., has filed its unaudited condensed interim financial statements for the three and nine months ended April 30, 2024.
• The company was incorporated on May 15, 2023, and is a pre-clinical immuno-oncology biotechnology company.
• BriaPro's assets include Bria-TILsRx and PKC inhibitors for multiple indications, including cancer.
• The company's total assets as of April 30, 2024, were $203,614, with a total shareholders' deficit of $301,924.
• For the nine months ended April 30, 2024, BriaPro reported a net loss of $316,517, with research and development expenses of $227,249 and general and administrative expenses of $139,711.
• The company's cash and cash equivalents remained at $1 during the nine-month period.
• BriaPro is currently in the pre-clinical research stage and has not commenced commercial operations.
• The company's ability to continue as a going concern is dependent on its ability to raise capital and achieve profitable operations.
• BriaPro expects to initiate human clinical studies for Bria-TILsRx in the first half of 2025 and for PKC inhibitors in the second half of 2025.

Sentiment

Score: 4

Explanation: The document highlights the potential of BriaPro's technology and future plans, but the current financial situation and reliance on future capital raises temper the overall sentiment. The company is in a high-risk, high-reward situation.

Positives

• BriaPro is developing novel multi-specific binding reagents (Bria-TILsRx) and protein kinase C delta (PKC) inhibitors with potential for cancer treatment.
• The company is using artificial intelligence (AI) to enhance drug discovery and development.
• BriaPro has a transition services agreement with BriaCell to provide research and development and head office services.
• The company has a clear strategy to advance its drug candidates through preclinical and clinical studies.
• BriaPro's PKC inhibitors have shown activity against multiple RAS transformed tumors, which are present in a large percentage of human cancers.

Negatives

• BriaPro has incurred significant losses since incorporation, with a net loss of $316,517 for the nine months ended April 30, 2024.
• The company has a negative working capital of $356,733 as of April 30, 2024.
• BriaPro is currently in the pre-clinical stage and has not commenced commercial operations.
• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• BriaPro is reliant on third parties for manufacturing, development, and marketing capabilities.

Risks

• BriaPro's shares are not listed on any stock exchange, and there is no assurance that they will be in the future.
• The company has a limited operating history and no operating revenues.
• The clinical effectiveness and safety of BriaPro's products are not yet supported by extensive clinical data.
• BriaPro is reliant on third parties for manufacturing, development, and marketing capabilities.
• The company may face competition from other research teams and companies with greater resources.
• BriaPro is dependent on key personnel, and the loss of their services could adversely affect the business.
• The company may be subject to intellectual property litigation.
• BriaPro may not be able to obtain adequate financing on acceptable terms.
• The company is subject to regulatory risks and changes in laws and regulations.
• BriaPro is subject to product liability risks.
• The company is reliant on a transition services agreement with BriaCell, which could be terminated.
• BriaCell owns a significant majority of BriaPro's shares, which could influence corporate actions.
• BriaPro is subject to risks related to data security and privacy regulations.
• The company is subject to government price controls and other restrictions on pricing, reimbursement and access to drugs.

Future Outlook

BriaPro expects to initiate human clinical studies for Bria-TILsRx in the first half of 2025 and for PKC inhibitors in the second half of 2025. The company also plans to screen several multi-specific binding reagents and select at least one candidate to advance into IND enabling studies.

Management Comments

• Management believes that the functional currency of the Company is the U.S. dollar.
• Management asserts that BriaPro had not yet achieved commercial operations and was still in the Research stage at the time of the Arrangement.
• Management believes that the credit risk concentration with respect to financial instruments is remote.

Industry Context

This announcement reflects the ongoing trend of biotechnology companies focusing on innovative cancer therapies, particularly in the areas of immunotherapy and targeted treatments. The use of AI in drug discovery is also a growing trend in the industry, as companies seek to accelerate the development process and improve the efficacy of their drug candidates. The spin-out of BriaPro from BriaCell is a common strategy for companies to focus on specific assets and attract investment.

Comparison to Industry Standards

• BriaPro's financial position, with a significant accumulated deficit and negative working capital, is not uncommon for early-stage biotech companies focused on research and development.
• The company's reliance on third-party contract research organizations is a standard practice in the biotech industry to manage costs and access specialized expertise.
• The timeline for initiating human clinical trials in 2025 is typical for companies in the pre-clinical stage of drug development.
• The use of AI in drug discovery is becoming increasingly common, with companies like Recursion Pharmaceuticals and Exscientia leading the way in this area.
• BriaPro's focus on multi-specific binding reagents and PKC inhibitors aligns with the industry's interest in developing more targeted and effective cancer therapies, similar to companies like Amgen and Regeneron in the bispecific antibody space.

Related Party Transactions

• As of April 30, 2024, the balance owing to BriaCell group companies is $302,605, comprising fixed monthly services and direct expenses incurred by BriaCell on behalf of BriaPro.

Stakeholder Impact

• Shareholders face the risk of dilution from future capital raises.
• Employees are subject to the uncertainty of the company's financial stability.
• Customers (potential patients) may benefit from the development of new cancer therapies.
• Suppliers and creditors face the risk of non-payment if the company fails to secure additional funding.

Next Steps

• BriaPro expects to screen several different multi specific binding reagents for activity in vitro as well as in mouse models of cancer.
• BriaPro also expects to select at least one candidate to advance into IND enabling studies.
• Human clinical studies are expected to be initiated in the first half of 2025 for Bria-TILsRx.
• Human clinical studies are expected to be initiated in the second half of 2025 for PKC inhibitors.
• BriaPro will continue to optimize the structure of its proprietary protein kinase C delta inhibitors and advance to the candidates election stage.

Key Dates

Keywords

BriaPro Therapeutics, BriaCell, immuno-oncology, Bria-TILsRx, PKC inhibitors, cancer therapy, biotechnology, clinical trials, drug development, artificial intelligence, immunotherapy